Key result
St. Jude 19 mm valve is linked to ~26% LV mass reduction for BSA <1.6 m2.
Why the study?
The permissible range of the St. Jude Medical 19 mm valve as an aortic prosthesis required determination.
Does the St. Jude Medical 19 mm valve reduce left ventricular hypertrophy in patients with aortic valve disease and small body surface area?
Observational (n=21)
Does the St. Jude Medical 19 mm valve reduce left ventricular hypertrophy in patients with aortic valve disease and small body surface area?
The St. Jude Medical 19 mm valve reduces LV hypertrophy in patients with small body surface area (<1.6 m2), though exercise-induced pressure gradients warrant cautious use.
May support 19 mm valve use in small-BSA patients; leaves open long-term safety and exercise hemodynamics.
To determine the permissible range of the St. Jude Medical 19 mm valve (SJM19) as an aortic prosthesis, transvalvular maximal pressure gradient (maxPG) and postoperative reduction of left ventricular (LV) hypertrophy were examined in 21 patients (body surface area [BSA] 1.28-1.56 m2, mean 1.42 m2). Doppler echocardiographically measured maxPG at rest was 31 +/- 16 mmHg, which showed no significant difference from the differences in patients' diseases (aortic regurgitation = AR or stenosis = AS), or BSA. The maxPG, also measured during dobutamine administration when they were less than 40 mmHg at rest, increased significantly from 21 +/- 11 mmHg to 32.1 +/- 15 mmHg, having no differences from the differences in diseases or BSA. Reduction of LV hypertrophy was achieved postoperatively (mean postoperative period of ten months), with the reduction rates of 26 +/- 19% in LV mass and 21 +/- 15% in LV cross-sectional area. No significant differences were found between the reduction rates and the differences in the patients' diseases or BSA. These results indicate that, following the implantation of SJM19, LV hypertrophy was reduced in patients with AR as well as with AS, when their BSA values were less than 1.6 m2. However, limited use is recommended because the increase in pressure gradient during exercise cannot be ignored.
No takes yet. Share an insight, caveat, or question.
Ota et al. (1995) conducted an observational in Aortic regurgitation or stenosis (n=21). St. Jude Medical 19 mm valve (SJM19) prosthesis was evaluated on Transvalvular maximal pressure gradient and postoperative reduction of left ventricular hypertrophy. The St. Jude Medical 19 mm valve prosthesis reduced left ventricular mass by a mean of 26% at 10 months in patients with aortic valve disease and body surface area <1.6 m2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: